From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
Cancers2017Vol. 9(10), pp. 138–138
Citations Over TimeTop 25% of 2017 papers
Abstract
Anaplastic large cell lymphoma expressing anaplastic lymphoma kinase (ALK+ ALCL) is a distinct subtype of non-Hodgkin lymphoma. In this review, we discuss the historical findings that led to its classification as a unique disease, despite its varied clinical presentation and histology. We discuss the molecular mechanisms underlying ALK+ ALCL pathology and the questions that remain in the field. Finally, we visit how decades of ALK+ ALCL research has yielded more precise drugs that hold promise for the future.
Related Papers
- → Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib(2019)15 cited
- → From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)(2017)10 cited
- → Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative(2009)8 cited
- → An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive(2017)7 cited
- Alk- Negative, Anaplastic Large Cell Lymphoma- A Case Report(2015)